Ensituximab
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer[1][2].
Product Specifications
CAS Number
[1092658-06-4]
Product Name Alternative
Anti-MUC5AC Reference Antibody (ensituximab) ; NEO-102
UNSPSC
12352203
Target
Mucin
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ensituximab.html
Purity
99.93
Solubility
10 mM in DMSO
Smiles
[Ensituximab]
Molecular Weight
(142.82 kDa)
References & Citations
[1]Richard D Kim, et al. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Jul 15;26 (14) :3557-3564. |[2]Julian A Marin-Acevedo, et al. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018 Jan 12;11 (1) :8.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
